September 13, 2012
Pfizer Japan announced on September 12 that the company filed on September 7 an application for acute exacerbation of multiple sclerosis (MS), based on data from the public domain, as an additional indication for its adrenal corticosteroid Solu-Medrol for Intravenous...read more